Amy Donnelly
Family · Findlay, OHNPI 1871077255
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Corcept Therapeutics accounts for 89.3% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $30,963, more than ten times the $1,170 reported in 2021. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $115.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$32K
- AbbVie$836
- Novo Nordisk$647
- Otsuka America Pharmaceutical, Inc.$264
- Johnson & Johnson$227
- Pfizer$159
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$21,74560%
- Travel & lodging$7,60321%
- Food & beverage$7,04919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 95 | $32,490 |
| AbbVie | 53 | $836 |
| Novo Nordisk | 42 | $647 |
| Otsuka America Pharmaceutical, Inc. | 14 | $264 |
| Johnson & Johnson | 15 | $227 |
| Pfizer | 8 | $159 |
| AstraZeneca | 4 | $146 |
| Amgen | 4 | $144 |
| Abbott | 6 | $140 |
| Boston Scientific | 2 | $136 |
| GSK | 8 | $131 |
| Ironshore Pharmaceuticals Inc. | 3 | $107 |
| Dexcom, Inc. | 4 | $84 |
| Merck | 6 | $83 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Lilly USA, LLC | 5 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $69 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $49 |
| Exact Sciences | 3 | $49 |
| Corium, LLC | 4 | $49 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $38 |
| Bayer | 2 | $34 |
| Novartis | 2 | $33 |
| Axonics, Inc. | 1 | $32 |
| Boehringer Ingelheim | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Abiomed | 1 | $19 |
| Astellas Pharma US Inc | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Rhythm Pharmaceuticals, Inc. | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Bausch Health US, LLC | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$30,388
- WATCHMAN Access System$130
- BREZTRI$106
- UBRELVY$105
How this compares
$36,396 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 72 | $2,486,127 |
| JardianceEmpagliflozin | 76 | $95,282 |
| TrulicityDulaglutide | 50 | $61,287 |
| OzempicSemaglutide | 43 | $57,518 |
| JanuviaSitagliptin Phosphate | 34 | $50,443 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $44,167 |
| FarxigaDapagliflozin Propanediol | 30 | $38,553 |
| EliquisApixaban | 23 | $33,578 |
| MyrbetriqMirabegron | 26 | $16,087 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $11,147 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $10,282 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $8,393 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $8,309 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,742 |
| Atorvastatin Calcium | 416 | $4,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $32,490 | $2,486,12772 claims |
| Boehringer IngelheimJardiance | $28 | $95,28276 claims |
| Lilly USA, LLCTrulicity | $73 | $61,28750 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $131 | $58,21872 claims |
| Novo NordiskOzempic | $647 | $57,51843 claims |
| MerckJanuvia | $83 | $50,44334 claims |
| AstraZenecaFarxiga, Symbicort | $146 | $42,85044 claims |
| PfizerEliquis | $159 | $33,57823 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $16,08726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Findlay
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
- Kirt MunsonToledo$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.